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EDITORIALCarotid Intima-media Thickness and/or Carotid Plaque: What is Relevant?Carotid intima-media thickness (CIMT) is often used as a
risk predictor for cardiovascular complications in epidemi-
ological studies. It has also served as a surrogate marker in
the testing of novel anti-atherosclerotic pharmaceutical
compounds, where halting CIMT growth (or regression) is
interpreted as a positive beneﬁcial effect. Finally, in some
primary prevention studies, CIMT is used to evaluate indi-
vidual risks for future cardiovascular complications. How-
ever, recently published data are now questioning the
relevance of CIMT in individual patient management.
CIMT measurement was introduced as a research tool
three decades ago and was based on the principle that
atherosclerosis begins with a gradual accumulation of lipid
in the arterial wall resulting in universal or localized thick-
ening. Including the arterial media within the measurement
was actually a technical matter, because ultrasound was not
able (at that time) to discriminate between intima and
media, rather than wrongly assuming that the atheroscle-
rotic process affected the media as well.1 This is an
important point, as both the intima and the media may
thicken for different reasons: intima because of accumula-
tion of lipids (atherosclerosis) and media because of hy-
pertrophy of smooth muscle cells (hypertension/
remodelling).
Historically, CIMT was measured on the anterior and
posterior walls at three anatomical locations: the distal
common carotid artery (CCA), the proximal internal carotid
artery (ICA), and the external carotid artery (ECA). The six
CIMT values from each carotid artery were then combined
and averaged into a single CIMT value, thereby reﬂecting
the atherosclerotic burden of both carotid arteries in the
patient. In later revisions to practice, the number of mea-
surement sites was reduced and current guidelines
recommend only imaging the posterior wall of the distal
10 mm of the CCA.2e4
The rationale underpinning this change in practice was
that the best resolution/sharpest images were obtained
when scanning the vessel wall at a 90 degree angle (be-
tween the direction of the emitted ultrasound waves and
the reﬂecting anatomical structure). Even though the ca-
rotid bulb and ICA are more prone towards developing
atherosclerosis, an estimation of IMT in these regions would
be less accurate because of the branching angle of the ICA
from the CCA, which runs more or less parallel to the skin
surface in the majority of people. A single CCA CIMT mea-
surement method was found to be reasonably reproducible,
giving robust data for large populations of patients The
average variability for repeated measurements was 0.06e
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ering that CIMT values between 0.5 and 0.8 mm are
considered to be within the normal range, individual vari-
ability can turn out to be quite considerable. CIMT has been
reported as the maximum CIMT (at any point within the
10 mm CCA segment) and the mean CIMT. The latter
measurement is recommended as being the more robust.
Automated edge detection software improves reproduc-
ibility and, more recently, greater focus has been directed
towards achieving a clear discrimination between CIMT
assessment and atherosclerotic plaque.6
In epidemiological studies, CIMT measurement was evalu-
ated to seewhether it could better predict cardiovascular and/
or cerebrovascular outcomes than traditional risk factors, such
as those identiﬁed in the Framingham Study: sex, age, smok-
ing, blood pressure, LDL and HDL cholesterol, and diabetes. By
adding in a measurement of CIMT, it has been possible to
achieve incremental prediction over the Framingham Risk
Score (FRS) alone for groups of people. Generally, the group
with the lowest IMT experience fewer late cardiovascular
events (death, myocardial infarction, stroke, new angina, etc.)
compared with those with the highest IMT quartiles/quin-
tiles.3,5,7e9 However, the predictive value for an individual
person seems limited e if it exists at all.
In the Cardiovascular Risk Prediction Study (CAPS), the
group with the highest CIMT did have a slightly higher risk of
cardiovascular complications than those with the lowest
CIMT. However, risk assessment for the individual participant
was unaltered by CIMTmeasuremente even after 10 years of
follow-up.10 Similarly, other studies have found little if any
incremental value of measuring CIMT; most often expressed
as a net reclassiﬁcation of risk assessment by traditional risk
factors.11,12 For instance, comparing different methods for
risk assessment in the Multi Ethnic Study of Atherosclerosis
(MESA) study, the coronary calcium score (CACS), the ankle
brachial index (ABI), CRP, and family history were all inde-
pendent risk predictors; however, CIMT was not.12 Similarly,
the High-Risk Plaque Study, which included 6,100 asymp-
tomatic Americans with an average age of 69 years, found
that CIMT had no predictive value over FRS, whereas the
coronary artery calcium score (CACS) and carotid plaque
burden (a measure of the amount of carotid plaque, as
assessed by several cross-sectional images), were highly
predictive of the development of late atherosclerotic com-
plications.13e15 In fact, the mere presence of plaque in the
carotid artery has, for a long time, been known to be much
more predictive of an adverse cardiovascular outcome than
that of the thickest CIMT group.3,7,11
According to Peters,16 the value of adding CIMT to the
FRS (expressed as the Net Reclassiﬁcation Improvement),
varied considerably from zero to 12% and was less consis-
tent and of a smaller magnitude compared with carotid
plaque presence and CACS. Similarly, den Ruijter concluded
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was associated with a small improvement in the 10-year risk
prediction for ﬁrst-time MI or stroke, this improvement in
risk prediction was unlikely to be of clinical importance.17
For these reasons, the latest primary prevention recom-
mendations from the American College of Cardiology/
American Heart Association advises against using CIMT
measurement for predicting individual cardiovascular risk
prediction on the basis that it is not useful and could be
potentially harmful.18 Finally, serial CIMT measurements (in
order to follow IMT progression with time) have been
removed from contemporary recommendations by Euro-
pean and American expert groups.3,4 In addition, the
“PROG-IMT collaborative project”, based on 16 studies
including 37,000 people/patients, advised that serial CIMT
measurements were not useful for predicting future car-
diovascular events.19
So, given that atherosclerosis involves arterial wall
thickening, why is it that CIMT measurement does not
reliably predict cardiovascular outcomes when the simple
presence of a carotid plaque is such a powerful predictor?
There are at least three explanations: (i) considering the
beam width of focused ultrasound (1e2 mm) and the CCA
diameter, the resulting IMT measurement will only repre-
sent a small part of the CCA vessel wall circumference.
Atherosclerosis does not develop as a uniform, circumfer-
ential thickening of the vessel wall and does not consis-
tently localise to the anterior or posterior wall regions.
Accordingly, assessment of CIMT will be greatly inﬂuenced
by which part of the arterial circumference is being inso-
nated; (ii) the atherosclerotic process predominantly affects
the intima and, thus, the inclusion of media thickness
measurements could confound meaningful interpretation;
(iii) uniform thickening of the arterial wall will not predis-
pose towards a higher risk of acute thrombosis as would
rupture of the ﬁbrous cap within a vulnerable plaque.
So, is there any role for CIMT measurement? For
assessment of CIMT in younger persons at increased risk of
cardiovascular disease, a thick IMT will indicate true thick-
ening, provided measurement is performed using an inso-
nation angle of 90 degrees and ensuring capture through
the centre of the artery. However, a thin or “normal” IMT
could simply be the result of scanning an area without
thickening or plaque, therefore being misleading, and serial
measurements are not helpful because of inter-scan vari-
ability. For vascular surgeons, therefore, IMT measurement
probably has no clinical value.
Is ultrasound scanning of the carotid artery for assessment
of carotid plaques of any use in cardiovascular risk predic-
tion? The increased risk of atherosclerotic complications in
patients with carotid stenosis has been recognized for de-
cades and, in 2001, carotid stenoses (including asymptomatic
lesions) were classiﬁed as being a “coronary risk equivalent”.
This implies a similar long-term risk to patients with clinical
coronary disease and appropriate secondary prevention
strategies should be implemented.20 Even though the risk of
ipsilateral stroke is declining, cardiovascular risk (in general)
remains increased in patients with asymptomatic carotidstenosis.21e24 The mere presence of a carotid plaque is a
much stronger predictor of cardiovascular complications,
compared with CIMT and other more conventional risk fac-
tors for atherosclerosis. A carotid plaque (deﬁned as a local
protrusion of at least 0.5mm, a 50% local thickening of IMTor
a CIMT >1.5 mm3,4) is associated with a doubling of the risk
of late cardiovascular events.3,7 Furthermore, different ways
of quantifying plaque size, that ismeasuring plaque area from
two-dimensional B-mode images, suggests that the greater
the plaque size, the greater the risk of late cardiovascular
events.24e26 More recently, quantiﬁcation of plaque size
from both carotids has been found to be as predictive of
major cardiovascular events as the coronary calcium score,
the current golden standard for risk prediction.15 Four
studies, including more than 29.000 people, uniformly shows
that the addition of ultrasound imaging for carotid plaque to
FRS results in signiﬁcant reclassiﬁcation. 7,11,15,26 With all the
recent advances of ultrasound over CT, the use of carotid
ultrasound to identify those in need of primary prevention
may result in much more effective treatment.
It is now accepted that the use of atherosclerosis risk
factors for predicting cardiovascular risk is not accurate.27
More important seems to be that the individual patient’s
susceptibility towards developing atherosclerosis may
reﬂect whether the patient can resist these risk factors or
not. Unfortunately, there is no test for “atherosclerosis
susceptibility”. It was long hoped that genetic testing would
become the solution; however, this has remained disap-
pointing. Instead, imaging the carotid arteries reveals who is
actually developing atherosclerotic disease and, because of
the slow nature of the plaque build-up, the time window for
therapeutic intervention is substantial.28 The most impor-
tant piece of missing information, however, is the trial that
will show whether a screened population fares any better
than an unscreened. Unfortunately, such a trial will prob-
ably fail because those in the control group will likely get
treated at some stage or seek screening themselves.
In conclusion, evidence supporting a role for CIMT mea-
surement in individual patients is poor. However, assessment
of carotid arteries for the presence and volume of plaque
seems very much more promising for directing enhanced
primary prevention strategies to those who really need it.REFERENCES
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